GENERAL INFORMATION

The aim of BOCCS is to stimulate collaboration between Belgian Institutes by creating a cooperation aiming at exploring therapeutic outcomes, diagnostic methods or epidemiological parameters of challenging clinical problems with unclear evidence-based/ harmonized protocols by pooling /sharing samples and models between the participating centers. The outcomes should benefit the Belgian Ophthalmologists in their daily practice and improve optimal use of Social Security resources. The collaborating teams should follow the ICH-GCP regulations and requirements applicable at the time of submission. BOCCS is a two-year assignment program with an option to apply for a second round of funding. **BOCCS projects are collaborative, clinical projects involving two or more Belgian centers of expertise. If successful, the maximum amount of money allocated to such projects also depends on the number of centers involved, beyond the quality and topic of the research project\*p5.**

Timeline & deadlines:

* + Submission of preliminary call 30 June 2022, before midnight
	+ Preselection by international jury 31 July 2022
	+ Final submission of successful applications 15 October 2022, before midnight
	+ Selection of final successful projects 15 November 2022
	+ Announcement of final successful projects 25 November 2022 at OB2022 Congress
	+ Start of the funding 01 December 2022
	+ End of the funding 31 November 2023

A **Final Application Form (FAF)**, with indications as to what is required for the Preliminary Application and which additional information is required for the Final Application, can be found on the following page.

A shorter **Preliminary Application Form (PAF)**, with indications as to what is required for the Preliminary Application, can be found after the Final Application Form.

First submit the PAF. If your project is successful and selected for the final round, please submit the FAF by the deadline indicated above.

APPLICATION FORM FOR CALL

TITLE OF THE PROJECT:

ACRONYM:

SUMMARY (maximum of 500 words):

FIELD OF EXPERTISE NEEDED FOR EVALUATION (define at least 1 and maximum 2)

Gene therapy

Stem cell biology

Epidemiology

Sensory medicine

Medical biotechnology

Clinical outcomes

Quality Control

Other

KEYWORDS

**FINAL APPLICATION FORM**

**Should not exceed TWELVE pages (reference list excluded)**

Typewriting requirements:

 Font versions: Arial or Calibri

 Font size: 11

 Line spacing: 1.15

1. **Science &Technology EXCELLENCE**
	1. **CHALLENGE**
		1. MAIN AIM OF THE CHALLENGE

To be addressed in the **preliminary** application

* + 1. RELEVANCE AND TIMELINES

To be addressed in the **final** application

*Timelines:*

*1.1.2.1. Team building - Work plan - Ethical Committee approval - Electronic Study files- logistics - Newsletters*

 *1.1.2.2. Recruitment - communication between team members*

 *1.1.2.3. Interpretation - conclusion - publication - dissemination*

* 1. **OBJECTIVES**
		1. RESEARCH COORDINATION OBJECTIVES

To be addressed in the **preliminary** application

Describe the strategy how to reach the main aim of the challenge

* + 1. CAPACITY-BUILDING OBJECTIVES

To be addressed in the **preliminary** application

Describe how to implement the human and technical resources to reach the research coordination objectives

* 1. **PROGRESS BEYOND THE STATE-OF-THE-ART AND INNOVATION POTENTIAL**

To be addressed in the **preliminary** application

* + 1. DESCRIPTION OF THE STATE-OF-THE-ART
		2. PROGRESS BEYOND THE STATE-OF-THE-ART
		3. INNOVATION IN TACKLING THE CHALLENGE
	1. **ADDED VALUE OF NETWORKING**

To be addressed in the **preliminary** application

* + 1. IN RELATION TO THE CHALLENGE

Describe the added value of creating a network to reach the capacity-building objectives

* + 1. IN RELATION TO EXISTING EFFORTS AT NATIONAL AND/OR INTERNATIONAL LEVEL\*

**\***International collaboration is allowed to increase the chances of fulfilling the main aim of the challenge (to a maximum of 20% of the total budget)

1. **IMPACT**
	1. **EXPECTED IMPACT**
		1. SHORT-TERM AND LONG-TERM SCIENTIFIC, TECHNOLOGICAL AND / OR SOCIOECONOMIC IMPACTS

To be addressed in the **preliminary** application

* 1. **MEASURES TO MAXIMIZE IMPACT**

To be addressed in the **final** application

* + 1. PLAN FOR INVOLVING THE MOST RELEVANT STAKEHOLDERS\*

\*Stakeholders to be defined based on the main aim challenge e.g. national ophthalmological societies, industry partners, patient associations, European Reference Network, national authorities, academics

* + 1. Dissemination and/or exploitation plan
	1. **POTENTIAL FOR INNOVATION VERSUS RISK LEVEL**

To be addressed in the **preliminary** application

* + 1. POTENTIAL FOR SCIENTIFIC, TECHNOLOGICAL AND/OR SOCIOECONOMIC INNOVATION BREAKTHROUGHS
1. **IMPLEMENTATION**

To be addressed in the **final** application

**3.1 DESCRIPTION OF THE WORK PLAN**

3.1.1. DESCRIPTION OF WORKING GROUPS

3.1.2. GANTT DIAGRAM (minimum of required Working Groups (WG) is two)\*

|  |  |  |
| --- | --- | --- |
| WG Activities | Year 1 | Year 2 |
|  |  |  |  |  |  |  |  |
| WG1 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |
| WG2 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |
| WG3 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |
| WG4 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |
| WG5 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |
| WG6 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |
| WG7 | Tasks |  |  |  |  |  |  |  |  |
| Deliverables |  |  |  |  |  |  |  |  |
| Milestones |  |  |  |  |  |  |  |  |

 3.1.3. RISK AND CONTINGENCY PLANS

 To be addressed in the **preliminary** application

|  |  |  |  |
| --- | --- | --- | --- |
| Risk | Probability | Impact | Mitigation measures |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**3.2.** **MANAGEMENT STRUCTURES AND PROCEDURES**

To be addressed in the **final** application

 Describe the following structures:

* Management Committee (MC) consisting of:

Principle investigator (PI) and Co-investigators (Co-I) of each participating centers will liaise with the executives of the FRO

* Scientific steering group (SSG) consisting of (MC) and participating staff and allied personnel. Distribution of the tasks – deliverables and milestones will be managed by the SSG

**3.3. NETWORK AS A WHOLE**

To be addressed in the **final** application

 Extensive description of all partners who have committed themselves to the project

**REFERENCES**

To be addressed in the **preliminary** application

**NUMBER OF EARLY CAREER (not yet PhD degree) INVESTIGATORS PER PARTICIPATING CENTER**

To be addressed in the **final** application

**NUMBER OF EXPERTS PER PARTICIPATING CENTER**

To be addressed in the **final** application

 FIELD OF SCIENCES

* CLINICIANS (MD / PHD)
* OTHER SCIENCE DEPARTMENTS
* ALLIED PROFESSIONS

PRELIMINARY APPLICATION FORM

**Should not exceed FOUR pages (reference list excluded)**

Typewriting requirements:

 Font type: Arial or Calibri

 Font size: 11

 Line spacing: 1.15

**1. Science & Technology EXCELLENCE**

 **1.1. CHALLENGE**

* + 1. MAIN AIM OF THE CHALLENGE

To be addressed in the **preliminary** application

* 1. **OBJECTIVES**
		1. RESEARCH COORDINATION OBJECTIVES

To be addressed in the **preliminary** application

Describe the strategy how to reach the main aim of the challenge

* + 1. CAPACITY-BUILDING OBJECTIVES

To be addressed in the **preliminary** application

Describe how to implement the human and technical resources to reach the research coordination objectives

* 1. **PROGRESS BEYOND THE STATE-OF-THE-ART AND INNOVATION POTENTIAL**

To be addressed in the **preliminary** application

* + 1. DESCRIPTION OF THE STATE-OF-THE-ART
		2. PROGRESS BEYOND THE STATE-OF-THE-ART
		3. INNOVATION IN TACKLING THE CHALLENGE
	1. **ADDED VALUE OF NETWORKING**

To be addressed in the **preliminary** application

* + 1. IN RELATION TO THE CHALLENGE

Describe the added value of creating a network to reach the capacity-building objectives

* + 1. IN RELATION TO EXISTING EFFORTS AT NATIONAL AND/OR INTERNATIONAL LEVEL\*

**\***International collaboration is allowed to increase the chances of fulfilling the main aim of the challenge (to a maximum of 20% of the total budget)

1. **IMPACT**
	1. **EXPECTED IMPACT**
		1. SHORT-TERM AND LONG-TERM SCIENTIFIC, TECHNOLOGICAL AND / OR SOCIOECONOMIC IMPACTS

To be addressed in the **preliminary** application

* 1. **MEASURES TO MAXIMIZE IMPACT (Not required for preliminary application)**
	2. **POTENTIAL FOR INNOVATION VERSUS RISK LEVEL**

To be addressed in the **preliminary** application

* + 1. POTENTIAL FOR SCIENTIFIC, TECHNOLOGICAL AND/OR SOCIOECONOMIC INNOVATION BREAKTHROUGHS
1. **IMPLEMENTATION**

To be addressed in the **final** application except 3.1.3.

 3.1.3. RISK AND CONTINGENCY PLANS

 To be addressed in the **preliminary** application

|  |  |  |  |
| --- | --- | --- | --- |
| Risk | Probability | Impact | Mitigation measures |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**REFERENCES (number of pages are excluded from the FOUR pages allowed for the preliminary application)**

To be addressed in the **preliminary** application and completed, if required, for the final application